Free Trial
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

Amicus Therapeutics logo
$6.22 +0.17 (+2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$6.22 +0.00 (+0.08%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Key Stats

Today's Range
$6.04
$6.25
50-Day Range
$5.64
$7.68
52-Week Range
$5.51
$12.65
Volume
4.19 million shs
Average Volume
3.19 million shs
Market Capitalization
$1.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.22
Consensus Rating
Moderate Buy

Company Overview

Amicus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

FOLD MarketRank™: 

Amicus Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 263rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amicus Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Amicus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Amicus Therapeutics are expected to grow by 186.67% in the coming year, from $0.15 to $0.43 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amicus Therapeutics is -69.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amicus Therapeutics is -69.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amicus Therapeutics has a P/B Ratio of 9.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amicus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.94% of the float of Amicus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Amicus Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Amicus Therapeutics has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Amicus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Amicus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.94% of the float of Amicus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Amicus Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Amicus Therapeutics has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Amicus Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    7 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Amicus Therapeutics, Inc. (FOLD) - Yahoo Finance
See More Headlines

FOLD Stock Analysis - Frequently Asked Questions

Amicus Therapeutics' stock was trading at $9.42 on January 1st, 2025. Since then, FOLD stock has decreased by 34.0% and is now trading at $6.22.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics's revenue was up 34.0% compared to the same quarter last year.
Read the conference call transcript
.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
7/08/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CIK
1178879
Employees
480
Year Founded
2002

Price Target and Rating

High Price Target
$22.00
Low Price Target
$9.00
Potential Upside/Downside
+160.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
41.47
P/E Growth
N/A
Net Income
-$56.11 million
Pretax Margin
-0.59%

Debt

Sales & Book Value

Annual Sales
$543.14 million
Price / Cash Flow
N/A
Book Value
$0.65 per share
Price / Book
9.57

Miscellaneous

Free Float
301,157,000
Market Cap
$1.92 billion
Optionable
Optionable
Beta
0.51

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:FOLD) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners